+++
title = "Consumer group says drugmakers abuse U.S. patent system to keep prices high"
description = "Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate prices, a consumer group said on Thursday,"
date = "2022-09-16 12:28:55"
slug = "63246be2c65513e9a7a63aca"
image = "https://i.imgur.com/c89t4EE.jpg"
score = "2728"
categories = ['selling', 'patents', 'squibb']
+++

Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate prices, a consumer group said on Thursday,

## Highlights

- Initiative for Medicines, Access & Knowledge said three of the top 10 selling drugs in the U.S.
- face no competition in the country.
- Drugmakers have used the practice of seeking multiple patents for minor variations on a single invention, known as patent thickets, to stave off generic competition for decades.
- The Swiss competition commission (COMCO) on Thursday opened an investigation into Novartis over possible unlawful use of a patent to reduce competitive pressure.
- The group called on lawmakers and government agencies to end patent thicket and modernize the patent system.
- The report was published by non-profit group I-MAK, funded by groups critical of pharmaceutical industry.

---

{{< rawhtml >}}
  <p class="article-category">
    <a target="_blank" href="https://www.reuters.com/business/healthcare-pharmaceuticals/consumer-group-says-drugmakers-abuse-us-patent-system-keep-prices-high-2022-09-16/">READ THE ORIGINAL ARTICLE</a>
  </p>
{{< /rawhtml >}}
